Apr 23, 2019

Research and development for prescription drugs is thriving

Caitlin Owens, author of Vitals

Photo: John Tlumacki/The Boston Globe via Getty Images

In 2018, a record 59 new drugs were launched — a portfolio that makes it clear that development is increasingly geared toward specialty drugs, according to a new IQVIA report.

By the numbers: Almost half launched with orphan drug status for the use that was being approved, meaning they were designed to serve small patient populations.

  • Oncology was the therapy with the most new launches — 16 — followed by infectious disease, which saw 12 launches.
  • One-third were identified as first-in-class, and 39 were specialty drugs.
  • A little less than half were approved based on trials with less than 500 people.

Small biopharmaceutical companies are playing an increasing role in the R&D ecosystem.

  • Emerging drug companies held the initial patents on 64% of the drugs launched in 2018, but about half of last year's drugs ultimately came to market via a larger pharma company.

Big Pharma is spending a huge amount on R&D. The top 15 largest companies spent more than $100 billion on R&D for the first time last year.

Go deeper: Pharma's research budgets are usually bigger than its profits

Go deeper

Updates: George Floyd protests continue past curfews

Protesters on Tuesday evening by the metal fence recently erected outside the White House. Photo: Olivier Douliery/AFP via Getty Images

Protests over the death of George Floyd and other police-related killings of black people continued Tuesday night across the U.S. for the eighth consecutive day — prompting a federal response from the National Guard, Immigration and Customs Enforcement and Customs and Border Protection.

The latest: The Army moved 1,600 soldiers from out of state into D.C. area, the Defense Department confirmed in a statement Tuesday. Protesters were still out en masse for mostly after curfews began in cities including Washington, D.C., New York City, Los Angeles and Portland.

Primary elections test impact of protests, coronavirus on voting

Election official at a polling place at McKinley Technology High School in Washington, D.C. Photo: Drew Angerer/Getty Images

In the midst of a global pandemic and national protests over the death of George Floyd, eight states and the District of Columbia held primary elections on Tuesday.

Why it matters: Joe Biden, the presumptive Democratic nominee, needs to win 425 of the 479 delegates up for grabs in order to officially clinch the nomination. There are a number of key down-ballot races throughout the country as well, including a primary in Iowa that could determine the fate of Rep. Steve King (R-Iowa).

Iowa Rep. Steve King defeated in GOP primary

Rep. Steve King. Photo: Alex Wroblewski/Getty Images

State Sen. Randy Feenstra defeated incumbent Rep. Steve King in Tuesday's Republican primary for Iowa's 4th congressional district, according to the Cook Political Report.

Why it matters: King's history of racist remarks has made him one of the most controversial politicians in the country and a pariah within the Republican Party.